肌节突变携带者与显性肥厚型心肌病的微结构与微血管表型
该多中心研究纳入206例受试者,包括101例显性HCM(51例G+LVH+和50例G-LVH+)、77例G+LVH-和28例健康志愿者,采用定量灌注心脏磁共振和扩散张量成像评估心肌微结构与微血管功能。结果显示显性HCM存在微结构改变和微血管病,G+与G-患者不同;G+LVH-携带者虽无肥厚但已有微结构改变和微血管病,且与心电图异常相关。
要点
- 显性HCM患者存在微结构改变和微血管病,G+与G-患者表型不同。
- 肌节突变携带者无肥厚时已出现微结构改变和微血管病。
- 微结构与微血管改变与心电图异常独立相关。
核心结论
- 微结构改变和微血管病发生于显性HCM,且在G+与G-患者中不同。
- 肌节突变携带者无肥厚时已出现微结构改变和微血管病,并与心电图异常相关。
研究设计与样本
- 多中心研究纳入206例受试者:101例显性HCM(51例G+LVH+和50例G-LVH+)、77例G+LVH-和28例匹配健康志愿者。
- 所有受试者接受12导联心电图、定量灌注心脏磁共振和心脏扩散张量成像。
主要发现
- 与健康志愿者相比,显性HCM患者 fractional anisotropy 更低、mean diffusivity 更高、second eigenvector angle 更高(均P<0.001)。
- 显性HCM患者 stress myocardial blood flow 和 myocardial perfusion reserve 更低(均P<0.001)。
- G-LVH+与G+LVH+相似,但second eigenvector angle更高(调整LVH和纤维化后P<0.001)。
- 显性HCM中灌注缺损在G+患者为100%(51/51),G-患者为82%(41/50),P=0.001。
- G+LVH-携带者较健康志愿者有微结构改变(所有DTI参数P<0.001)和微血管病(stress MBF降低P=0.015;灌注缺损28% vs 0,P=0.002)。
关键数值与推荐
- 显性HCM中 fractional anisotropy 与异常ECG的OR为3.3(P=0.01),stress MBF的OR为2.8(P=0.015)。
- 亚临床HCM中 fractional anisotropy 与异常ECG的OR为4.0(P=0.001),myocardial perfusion reserve的OR为2.2(P=0.049)。
临床怎么用
- 心肌微结构和微血管功能的可测量变化可作为早期表型生物标志物。
- 在疾病修饰治疗时代,有助于检测表型发展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In hypertrophic cardiomyopathy (HCM), myocyte disarray and microvascular disease (MVD) have been implicated in adverse events, and recent evidence suggests that these may occur early. As novel therapy provides promise for disease modification, detection of phenotype development is an emerging priority. To evaluate their utility as early and disease-specific biomarkers, we measured myocardial microstructure and MVD in 3 HCM groups-overt, either genotype-positive (G+LVH+) or genotype-negative (G-LVH+), and subclinical (G+LVH-) HCM-exploring relationships with electrical changes and genetic substrate. METHODS: This was a multicenter collaboration to study 206 subjects: 101 patients with overt HCM (51 G+LVH+ and 50 G-LVH+), 77 patients with G+LVH-, and 28 matched healthy volunteers. All underwent 12-lead ECG, quantitative perfusion cardiac magnetic resonance imaging (measuring myocardial blood flow, myocardial perfusion reserve, and perfusion defects), and cardiac diffusion tensor imaging measuring fractional anisotropy (lower values expected with more disarray), mean diffusivity (reflecting myocyte packing/interstitial expansion), and second eigenvector angle (measuring sheetlet orientation). RESULTS: Compared with healthy volunteers, patients with overt HCM had evidence of altered microstructure (lower fractional anisotropy, higher mean diffusivity, and higher second eigenvector angle; all P<0.001) and MVD (lower stress myocardial blood flow and myocardial perfusion reserve; both P<0.001). Patients with G-LVH+ were similar to those with G+LVH+ but had elevated second eigenvector angle (P<0.001 after adjustment for left ventricular hypertrophy and fibrosis). In overt disease, perfusion defects were found in all G+ but not all G- patients (100% [51/51] versus 82% [41/50]; P=0.001). Patients with G+LVH- compared with healthy volunteers similarly had altered microstructure, although to a lesser extent (all diffusion tensor imaging parameters; P<0.001), and MVD (reduced stress myocardial blood flow [P=0.015] with perfusion defects in 28% versus 0 healthy volunteers [P=0.002]). Disarray and MVD were independently associated with pathological electrocardiographic abnormalities in both overt and subclinical disease after adjustment for fibrosis and left ventricular hypertrophy (overt: fractional anisotropy: odds ratio for an abnormal ECG, 3.3, P=0.01; stress myocardial blood flow: odds ratio, 2.8, P=0.015; subclinical: fractional anisotropy odds ratio, 4.0, P=0.001; myocardial perfusion reserve odds ratio, 2.2, P=0.049). CONCLUSIONS: Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy.
引用
- Joy G, Kelly CI, Webber M, et al. Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy. Circulation. 2023. PMID: 37463608. doi:10.1161/CIRCULATIONAHA.123.063835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。